Questions we get asked.

A longitudinal imaging platform for oncology. We turn a patient's stream of CT and PET-CT studies into a structured, time-aware record, and we package clinical applications on top of that record — the first being an incidental lung nodule workflow.

Nexus is the platform layer. It handles DICOM ingestion, multi-organ segmentation and radiomics, persistent per-patient state, and guideline-aware decision logic. Every Hiveomics application is built on top of Nexus.

Lung nodules in production with detection, segmentation, classification, and the Malignancy Index. Lymph nodes (mediastinal, axillary, abdominal, inguinal), liver lesions, and kidney lesions in testing. 117-area whole-body segmentation runs on every CT study automatically.

In planning. The imaging, measurement, and guideline components that Navigator draws on are running and externally validated. The end-to-end clinical workflow assembled from them is not yet live at a partner site.

Standards-based DICOM Query/Retrieve (C-FIND, C-MOVE) for ingestion and STOW-RS for structured-report write-back. No rip-and-replace; Nexus sits alongside the existing radiology stack.

On-premise GPU server (one is enough for pilot throughput at ~6–10 studies per hour). Fully containerized via Docker Compose. Air-gapped capable; no external API calls required for the core pipeline.

It depends on PACS configuration, network policy, and what historical data is available for retrospective analysis. Concrete timelines are agreed in the partner conversation rather than promised on the site.

Studies stay inside the hospital. Role-based access, scoped service accounts, and an immutable audit trail for every model action and clinician confirmation. Designed to meet HIPAA and comparable European requirements.

Seven scientific outputs to date across ECR, Medical Alliance, and ESTS venues — external validation of the hamartoma and intrapulmonary lymph node classifiers, a prospective reader study on the Malignancy Index, and measurement equivalence against Canon Vitrea and GE AW Server. Evidence is ongoing, not a regulatory claim.

Not yet. The current focus is external validation, prospective reader studies, and the FDA CDS pathway for Navigator. Clearance milestones are reported when they happen, not before.

A per-study fee plus an annual platform fee. Specific numbers and discounting depend on volume, organ scope, and integration depth, and are handled in the partner conversation.

CPT 0721T (Category III) currently reimburses AI lung nodule tissue characterization at roughly $650 per study under Medicare. Category I codes for AI lung nodule detection on chest CT are arriving in 2026 — the inflection point from experimental to permanent reimbursement.

Hospitals, imaging groups, academic medical centers, and research collaborators weighing the platform against their oncology imaging pipeline. The initial conversation is a direct discussion, not a sales flow.

Yes. The investor inbox reaches the founding team directly. Round and instrument specifics stay off the public site.